Medifast (MED) Net Income towards Common Stockholders (2010 - 2026)

Medifast has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 174.16% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$20.0 million (down 184.92% YoY), and the FY2025 full-year result was -$18.6 million, down 991.39% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.1 million, up from -$18.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $41.8 million in Q1 2022, with the low at -$18.1 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged $13.2 million across 5 years, with a median of $6.0 million in 2023.
• The largest YoY upside for Net Income towards Common Stockholders was 130.37% in 2025 against a maximum downside of 2421.69% in 2025.
• Medifast's Net Income towards Common Stockholders stood at $26.5 million in 2022, then tumbled by 77.24% to $6.0 million in 2023, then plunged by 87.09% to $779000.0 in 2024, then slumped by 2421.69% to -$18.1 million in 2025, then jumped by 88.27% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$18.1 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.